Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Prostatic Neoplasms 90Breast Neoplasms 87Melanoma 86Multiple Myeloma 69Carcinoma, Non-Small-Cell Lung 63Leukemia, Myeloid, Acute 62Lymphoma 59Brain Neoplasms 57Glioblastoma 55Ovarian Neoplasms 51Neoplasms 51Carcinoma, Renal Cell 49Lymphoma, Non-Hodgkin 47Fallopian Tube Neoplasms 47Leukemia, Lymphocytic, Chronic, B-Cell 45Sarcoma 44Gliosarcoma 43Neoplasm Metastasis 39Lung Neoplasms 36Carcinoma, Hepatocellular 35Precursor Cell Lymphoblastic Leukemia-Lymphoma 34Pancreatic Neoplasms 33Glioma 33Lymphoma, Large B-Cell, Diffuse 32Uterine Cervical Neoplasms 31Hematologic Neoplasms 31Colonic Neoplasms 31Small Cell Lung Carcinoma 29Myelodysplastic Syndromes 28Rhabdomyosarcoma 27

Interventions

Taxes 1Paclitaxel 1Immunoglobulin G 1Gemcitabine 1Docetaxel 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Has results × Adenocarcinoma, Mucinous × Clear all
NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,052 enrolled 27 charts
Gynecologic

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡